药明生物再度蝉联晨星Sustainalytics 2024年“ESG行业最高评级”及“ESG区域最高评级”企业

Pharmaceutical Biotech once again ranked as the “highest ESG industry rating” and “highest ESG regional rating” company by Morningstar Sustainalytics in 2024

PR Newswire ·  Feb 20 21:13
  • Yao Ming Biotech has been ranked the “highest rating” for 4 consecutive years
  • The company will continue to work to create long-term value for all stakeholders

SHANGHAI, Feb. 21, 2024/PRNewswire/ -- WuXi Biologics (2269.HK), the world's leading contract research, development and production (CRDMO) service company, announced that it has been rated by Sustain Morningstar, an internationally renowned environmental, social and corporate governance (ESG) rating agency, as the “highest industry rating” and “highest rating in the region (Asia Pacific)” in 2024. This is also the fourth year in a row that the company has received this honor.

Sustainalytics is a leading provider of ESG data, research, and ratings to develop and implement responsible investment strategies for global investors. This year, Sustainalytics' ESG ratings covered more than 14,000 companies in 42 industries around the world, and selected companies that have achieved outstanding achievements in the ESG field were awarded the “Highest Rating” medal. Pharmaceutical Biotech has received high recognition from Sustainalytics, ranking in the top 2% of nearly 1,000 rated companies in the pharmaceutical industry.

CEO of Yao Ming Biotech,ESGChairman of the Committee Dr. Chan Chi-singHe said, “We are honored to receive the award from Morningstar Sustainalytics four times. This is a recognition of our continuous commitment to improving ESG capabilities and greatly promoting the company's sustainable development. “Yao Ming Biotech will continue to deploy comprehensive strategies and refined practices to consolidate the company's ESG management level, drive long-term sustainable business growth, and create greater value for global partners and the public.”

Yao Ming Biotech has always regarded ESG as the cornerstone of sustainable corporate development. In 2023, the company made significant progress in the ESG field: in June, the company announced the signing of the Scientific Carbon Targets Initiative (SBTi) commitment, steadily reaching a new milestone in net zero emissions; in September, Pharmaceutical Biotech joined the United Nations Global Compact to jointly advance broader UN goals through cooperation and partnership to fulfill its commitment to the sustainable development of enterprises and society. In addition, the company's ESG strategies and initiatives have also been recognized by global rating agencies — it was selected for the 2023 S&P Dow Jones Sustainability World Index (DJSI World), obtained the highest AAA rating in the ESG rating of MSCI (MSCI), and received the highest “platinum” rating from EcoVadis, an internationally authoritative corporate sustainability evaluation agency.

About MorningstarSustainalytics

Sustainalytics works with hundreds of the world's leading asset managers and pension funds to incorporate environmental, social, and corporate governance information and assessments into their investment processes. The company also works with hundreds of companies and their financial intermediaries to help them consider sustainability in their policies, practices, and capital projects. For more information, please visit.

Copyright 2024 Morningstar Sustainalytics. All rights reserved. This press release contains information developed by Sustainalytics (). This information and data is owned by Sustainalytics and/or its third party suppliers (third party data) and is for informational purposes only. This information and data does not constitute an endorsement of any product or project, nor investment advice, and there is no guarantee of its completeness, timeliness, accuracy, or suitability for a particular purpose. The use of third party data is subject to the conditions provided on the website.

About Yao Ming Biology

Medicinal Biotech (stock code: 2269.HK) is a leading global contract research, development and production (CRDMO) company. Through an open and integrated biopharmaceutical capability and technology empowerment platform, the company provides a full range of end-to-end services to help partners discover, develop and produce biopharmaceuticals, achieve the whole process from concept to commercial production, accelerate the global biopharmaceutical research and development process, reduce R&D costs, and benefit patients.

Yao Ming Biotech has more than 12,000 employees in China, the US, Ireland, Germany and Singapore. Through Pharmaceutical Biotech's professional service team, as well as advanced technology and deep insight, the company provides customers with efficient and economical biopharmaceutical solutions. By the end of December 2023, Yao Ming Biotech helped customers develop and produce 698 comprehensive projects, including 24 commercial production projects.

Pharmacology regards environmental, social and governance (ESG) as an important part of business development and corporate spirit, and is committed to becoming an ESG leader in the global biopharmaceutical CRDMO field, such as applying greener and more environmentally friendly next-generation biopharmaceutical technology and energy to lead the development of the industry. The company set up an ESG committee headed by the CEO to fully implement the ESG strategy and fulfill its commitment to sustainable development. For more information, please visit:.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment